Drug Type Small molecule drug |
Synonyms Pemrametostat + [2] |
Target |
Mechanism PRMT5 inhibitors(Protein arginine methyltransferase 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H32N6O3 |
InChIKeyJLCCNYVTIWRPIZ-NRFANRHFSA-N |
CAS Registry1616392-22-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | - | - | |
Acute Myeloid Leukemia | Phase 2 | - | - | |
Myelodysplastic Syndromes | Phase 2 | - | - | |
Myelodysplastic Syndromes | Phase 2 | - | - | |
Solid tumor | Phase 1 | US | 30 Aug 2016 | |
Solid tumor | Phase 1 | FR | 30 Aug 2016 | |
Solid tumor | Phase 1 | NL | 30 Aug 2016 | |
Early Stage Breast Carcinoma | Discovery | CA | 08 Jun 2021 | |
Non-Hodgkin Lymphoma | Discovery | US | - | 12 Apr 2021 |
Phase 1/2 | 30 | (tnkgnhleik) = tupudahkyn nptxgxuydy (hmpszijqos ) Met View more | Negative | 01 Jan 2024 | |||
Phase 1 | 218 | (TNBC) | (kcrpzhlwmy) = yhybojxxpx pstbeiynry (kplqzuoloy ) | Positive | 12 Sep 2022 | ||
(mTCC) | (kcrpzhlwmy) = bhxmntyepj pstbeiynry (kplqzuoloy ) | ||||||
Phase 1 | 54 | (aldgclbypx) = anemia (n = 8 [15%]), thrombocytopenia, neutropenia, and fatigue (each n = 4 [7%]) lkigqlqqmy (ghvuxvuhkd ) View more | Positive | 29 Sep 2019 |